• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Akumin Provides Business Update and Announces CFO Transition

    8/12/22 5:56:00 PM ET
    $AKU
    $ELV
    $SGRY
    Medical Specialities
    Health Care
    Medical Specialities
    Health Care
    Get the next $AKU alert in real time by email

    PLANTATION, Fla., Aug. 12, 2022 /PRNewswire/ - Akumin Inc. (NASDAQ:AKU) (TSX:AKU) ("Akumin" or the "Company") provided a business update and announced the termination of employment of its Chief Financial Officer, William Larkin and the appointment of David Kretschmer as Interim Chief Financial Officer, effective today.

    The Company has implemented a transformation program with initiatives focused on its operations, growth, and capital. These initiatives are intended to support the Company's objectives with respect to patient access and experience, customer and partner engagement, financial sustainability, and employee well-being. The Company is receiving support from a globally recognized transformation specialist to help implement the program. As a part of this transformation, the Company announced: (a) the termination of employment of its Chief Financial Officer, William Larkin, and the appointment of David Kretschmer, an experienced transformation finance executive who successfully completed other business transformations in the healthcare industry, as Interim Chief Financial Officer, effective today; and (b) the sale of certain accounts receivables by subsidiaries of the Company to a third-party buyer for a purchase price of approximately $30 million.

    Riadh Zine, Chairman and Chief Executive Officer of Akumin, commented: "Our transformation efforts to date have already resulted in significant efficiencies to our operations and show a positive momentum for further efficiencies, as discussed in our second quarter results.  I am very excited to welcome David as our new Interim Chief Financial Officer. We are thrilled to have his expertise complement our team as we successfully execute our transformation program. On behalf of the board of directors of Akumin, I would also like to thank Bill for his contributions to the Company and wish him the very best in his next endeavors."

    Mr. Zine continued: "The sale of certain accounts receivables has significantly improved the liquidity of our Company by an immediate cash infusion of approximately $30 million and a reduction in our days sales outstanding of our accounts receivables. Our cash position at the end of the second quarter of 2022 pro forma this sale would have been approximately $69 million. In addition, any future sale of similar accounts receivables in the normal course of business would not be expected to have any material impact on our revenues."

    Before joining the Company, Mr. Kretschmer previously worked for Surgery Partners, Inc. (NASDAQ:SGRY), a multi-specialty ambulatory surgical center company with $2.5 billion of revenues, as interim CFO and executive vice president of strategy and transformation, and, prior to that, as senior vice president, treasurer and CIO for Anthem, Inc. renamed Elevance Health, Inc. (NASDAQ:ELV), a health insurance provider with more than $130 billion of revenues, and he was a key team member in the execution of the successful business transformation of each of these companies.

    About Akumin

    Akumin is a national leader in comprehensive outpatient radiology and oncology solutions and a partner of choice for U.S. hospitals, health systems and physician groups. Akumin provides fixed-site outpatient radiology and oncology services through a network of 234 owned and/or operated centers; as well as outpatient radiology and oncology solutions to approximately 1,000 hospitals and health systems across 48 states. Akumin combines clinical and operational expertise with the latest advances in technology and information systems to deliver patient-centered innovation, service standardization and exceptional healthcare value to its patients and partners. For more information, visit www.akumin.com.

    Forward-Looking Information

    Certain information in this press release constitutes forward-looking information or forward-looking statements. In some cases, but not necessarily in all cases, such statements or information can be identified by the use of forward-looking terminology such as "plans", "targets", "expects" or "does not expect", "is expected", "an opportunity exists", "is positioned", "estimates", "intends", "assumes", "anticipates" or "does not anticipate" or "believes", or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might", "will" or "will be taken", "occur" or "be achieved". In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances contain forward-looking information. Statements containing forward-looking information are not historical facts but instead represent management's expectations, estimates and projections regarding future events.

    Forward-looking information is necessarily based on a number of opinions, assumptions and estimates that, while considered reasonable by Akumin as of the date of this press release, are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, level of activity, performance or achievements to be materially different from those expressed or implied by such forward-looking information, including, but not limited to, the factors described in greater detail in the "Risk Factors" section of our Quarterly Report on Form 10-Q for the period ended June 30, 2022, filed with the SEC on August 9, 2022,  which is available at www.sec.gov. These factors are not intended to represent a complete list of the factors that could affect Akumin; however, these factors should be considered carefully. There can be no assurance that such estimates and assumptions will prove to be correct. The forward-looking statements contained in this press release are made as of the date of this press release, and Akumin expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.

    Cision View original content:https://www.prnewswire.com/news-releases/akumin-provides-business-update-and-announces-cfo-transition-301605278.html

    SOURCE Akumin Inc.

    Get the next $AKU alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AKU
    $ELV
    $SGRY

    CompanyDatePrice TargetRatingAnalyst
    Elevance Health Inc.
    $ELV
    2/3/2026$358.00Outperform → Sector Perform
    RBC Capital Mkts
    Elevance Health Inc.
    $ELV
    1/8/2026$425.00Peer Perform → Outperform
    Wolfe Research
    Elevance Health Inc.
    $ELV
    12/19/2025$320.00Buy → Hold
    Deutsche Bank
    Elevance Health Inc.
    $ELV
    10/14/2025Neutral
    Goldman
    Surgery Partners Inc.
    $SGRY
    9/18/2025$27.00Neutral
    Analyst
    Surgery Partners Inc.
    $SGRY
    7/28/2025$28.00Buy
    BofA Securities
    Elevance Health Inc.
    $ELV
    7/21/2025Buy → Hold
    Argus
    Elevance Health Inc.
    $ELV
    7/18/2025$310.00Outperform → Market Perform
    Leerink Partners
    More analyst ratings

    $AKU
    $ELV
    $SGRY
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Devore Susan D. bought $374,580 worth of shares (1,200 units at $312.15), increasing direct ownership by 52% to 3,502 units (SEC Form 4)

    4 - Elevance Health, Inc. (0001156039) (Issuer)

    8/21/25 4:20:38 PM ET
    $ELV
    Medical Specialities
    Health Care

    President and CEO Boudreaux Gail bought $2,438,951 worth of shares (8,500 units at $286.94), increasing direct ownership by 6% to 151,020 units (SEC Form 4)

    4 - Elevance Health, Inc. (0001156039) (Issuer)

    7/18/25 1:42:51 PM ET
    $ELV
    Medical Specialities
    Health Care

    $AKU
    $ELV
    $SGRY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Elevance Health downgraded by RBC Capital Mkts with a new price target

    RBC Capital Mkts downgraded Elevance Health from Outperform to Sector Perform and set a new price target of $358.00

    2/3/26 6:49:01 AM ET
    $ELV
    Medical Specialities
    Health Care

    Elevance Health upgraded by Wolfe Research with a new price target

    Wolfe Research upgraded Elevance Health from Peer Perform to Outperform and set a new price target of $425.00

    1/8/26 8:09:47 AM ET
    $ELV
    Medical Specialities
    Health Care

    Elevance Health downgraded by Deutsche Bank with a new price target

    Deutsche Bank downgraded Elevance Health from Buy to Hold and set a new price target of $320.00

    12/19/25 8:44:26 AM ET
    $ELV
    Medical Specialities
    Health Care

    $AKU
    $ELV
    $SGRY
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    ZIEGLER ADVISES PREFERRED VASCULAR GROUP ON ITS ACQUISITION BY SURGERY PARTNERS

    CHICAGO, March 4, 2026 /PRNewswire/ -- Ziegler, a specialty investment bank, is pleased to announce that it served as the exclusive financial advisor to Preferred Vascular Group (PVG) in connection with its acquisition by Surgery Partners (NASDAQ:SGRY), a leading operator of surgical facilities and ancillary services. Founded in 2005, PVG is a leading Ambulatory Surgical Center (ASC) operator focused specifically on dialysis access procedures, with eight ASCs in Georgia and Ohio. Don Holton founded the Company after identifying a gap in dialysis access care and seeking to fill a

    3/4/26 4:00:00 PM ET
    $SGRY
    Hospital/Nursing Management
    Health Care

    Elevance Health and National Diaper Bank Network Launch National Pilot to Address Diaper Affordability and Improve Family Health

    National partnership will serve up to 9,000 families across 10 communities while reducing financial strain and studying impacts on maternal and child health Elevance Health (NYSE:ELV) and the National Diaper Bank Network (NDBN) today announced a new national pilot program designed to expand access to diapers for families with infants and young children, helping reduce financial strain while generating evidence on how meeting basic material needs can improve maternal and child health outcomes. The 12-month pilot program will provide free diapers to up to 75 families per month at 10 Welcome Rooms operated by Elevance Health affiliated Medicaid health plans in communities across the countr

    3/3/26 10:00:00 AM ET
    $ELV
    Medical Specialities
    Health Care

    Surgery Partners, Inc. Announces Fourth Quarter and Full Year 2025 Results; Sets 2026 Guidance; Announces Share Repurchase Program

    BRENTWOOD, Tenn., March 02, 2026 (GLOBE NEWSWIRE) -- Surgery Partners, Inc. (NASDAQ:SGRY) ("Surgery Partners" or the "Company"), a leading short-stay surgical facility owner and operator, today announced results for the fourth quarter and full year ended December 31, 2025. Fourth Quarter and Full Year 2025 Financial Highlights (All comparisons are year-over-year unless otherwise noted) Revenue increased 2.4% for the fourth quarter and 6.2% for the full year Same-facility revenues increased 3.5% for the fourth quarter and 4.9% for the full year Surgical cases decreased 2.1% for the fourth quarter and increased 2.0% for the full year Same-facility cases increased 1.3% for the fourth

    3/2/26 4:05:00 PM ET
    $SGRY
    Hospital/Nursing Management
    Health Care

    $AKU
    $ELV
    $SGRY
    SEC Filings

    View All

    SEC Form 10-K filed by Surgery Partners Inc.

    10-K - Surgery Partners, Inc. (0001638833) (Filer)

    3/2/26 5:11:59 PM ET
    $SGRY
    Hospital/Nursing Management
    Health Care

    Surgery Partners Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Surgery Partners, Inc. (0001638833) (Filer)

    3/2/26 4:55:31 PM ET
    $SGRY
    Hospital/Nursing Management
    Health Care

    SEC Form 8-K filed by Elevance Health Inc.

    8-K - Elevance Health, Inc. (0001156039) (Filer)

    3/2/26 6:03:41 AM ET
    $ELV
    Medical Specialities
    Health Care

    $AKU
    $ELV
    $SGRY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CAO & Controller Penczek Ronald W covered exercise/tax liability with 168 shares and was granted 2,393 shares, increasing direct ownership by 119% to 4,099 units (SEC Form 4)

    4 - Elevance Health, Inc. (0001156039) (Issuer)

    3/4/26 5:00:06 PM ET
    $ELV
    Medical Specialities
    Health Care

    EVP & Chief Legal Officer Wessling Erin M was granted 2,976 shares and covered exercise/tax liability with 417 shares, increasing direct ownership by 51% to 7,579 units (SEC Form 4)

    4 - Elevance Health, Inc. (0001156039) (Issuer)

    3/4/26 4:59:45 PM ET
    $ELV
    Medical Specialities
    Health Care

    EVP & Chief HR Officer Craig Ryan R covered exercise/tax liability with 334 shares and was granted 2,976 shares, increasing direct ownership by 66% to 6,674 units (SEC Form 4)

    4 - Elevance Health, Inc. (0001156039) (Issuer)

    3/4/26 4:59:14 PM ET
    $ELV
    Medical Specialities
    Health Care

    $AKU
    $ELV
    $SGRY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Elevance Health Inc.

    SC 13G/A - Elevance Health, Inc. (0001156039) (Subject)

    11/14/24 1:22:35 PM ET
    $ELV
    Medical Specialities
    Health Care

    Amendment: SEC Form SC 13G/A filed by Surgery Partners Inc.

    SC 13G/A - Surgery Partners, Inc. (0001638833) (Subject)

    11/8/24 10:46:38 AM ET
    $SGRY
    Hospital/Nursing Management
    Health Care

    SEC Form SC 13G filed by Surgery Partners Inc.

    SC 13G - Surgery Partners, Inc. (0001638833) (Subject)

    10/24/24 2:02:10 PM ET
    $SGRY
    Hospital/Nursing Management
    Health Care

    $AKU
    $ELV
    $SGRY
    Leadership Updates

    Live Leadership Updates

    View All

    Elevance Health Announces Management Changes; CFO Mark Kaye to Expand Responsibilities to Include Carelon and Felicia Norwood to Lead Consolidated Health Benefits Organization

    Elevance Health, Inc. (NYSE:ELV) today announced management changes designed to simplify decision-making and strengthen execution across Carelon and Health Benefits. As part of these changes, Mark Kaye, Executive Vice President and Chief Financial Officer, will expand his responsibilities to include oversight of Carelon, the Company's healthcare services operations including pharmacy services, behavioral health, value-based care, and care delivery capabilities. Carelon plays a critical role in advancing the Company's strategy to lower the cost of care. Carelon's operating priorities and client commitments remain unchanged. Felicia Norwood, Executive Vice President and Chief Health Benef

    2/26/26 3:02:00 PM ET
    $ELV
    Medical Specialities
    Health Care

    Elevance Health Board Welcomes Amy Schulman as New Director, Reflecting Ongoing Commitment to Governance Excellence

    The board of directors of Elevance Health (NYSE:ELV) today announced the appointment of Amy Schulman, a recognized healthcare executive, investor, and governance leader, as an independent director, effective January 12, 2026. Schulman will serve on the Audit and Finance Committees, contributing deep expertise in healthcare innovation, regulatory strategy, and value creation across complex, global enterprises. This appointment reflects Elevance Health's ongoing board refreshment strategy to ensure diverse, independent, and future-focused leadership that aligns with the company's long-term strategy and stakeholders' priorities. "Amy's record of driving innovation, disciplined investment, an

    12/10/25 4:30:00 PM ET
    $ELV
    Medical Specialities
    Health Care

    Surgery Partners, Inc. Names Laura L. Forese, MD to Board of Directors

    BRENTWOOD, Tenn., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Surgery Partners, Inc. (NASDAQ:SGRY) ("Surgery Partners" or the "Company") today announced that Dr. Laura L. Forese has been appointed to serve as an independent director on its Board of Directors. Dr. Forese's appointment, which is effective January 10, 2025, will increase the size of Surgery Partners' Board to eleven members. Dr. Forese joins the Surgery Partners Board with extensive healthcare experience. Her career in healthcare administration spans over 40 years, most recently serving as an executive vice president and chief operating officer for New York-Presbyterian, one of the nation's most comprehensive, integrated academic heal

    1/13/25 5:00:24 PM ET
    $SGRY
    Hospital/Nursing Management
    Health Care

    $AKU
    $ELV
    $SGRY
    Financials

    Live finance-specific insights

    View All

    Surgery Partners, Inc. Announces Fourth Quarter and Full Year 2025 Results; Sets 2026 Guidance; Announces Share Repurchase Program

    BRENTWOOD, Tenn., March 02, 2026 (GLOBE NEWSWIRE) -- Surgery Partners, Inc. (NASDAQ:SGRY) ("Surgery Partners" or the "Company"), a leading short-stay surgical facility owner and operator, today announced results for the fourth quarter and full year ended December 31, 2025. Fourth Quarter and Full Year 2025 Financial Highlights (All comparisons are year-over-year unless otherwise noted) Revenue increased 2.4% for the fourth quarter and 6.2% for the full year Same-facility revenues increased 3.5% for the fourth quarter and 4.9% for the full year Surgical cases decreased 2.1% for the fourth quarter and increased 2.0% for the full year Same-facility cases increased 1.3% for the fourth

    3/2/26 4:05:00 PM ET
    $SGRY
    Hospital/Nursing Management
    Health Care

    Surgery Partners, Inc. Announces Fourth Quarter 2025 Earnings Release Date and Conference Call Details

    BRENTWOOD, Tenn., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Surgery Partners, Inc. (NASDAQ:SGRY) ("Surgery Partners" or the "Company"), a leading short-stay surgical facility owner and operator, announced the Company will release its fourth quarter 2025 results after market close on Monday, March 2, 2026, to be followed by a conference call on Tuesday, March 3, 2026 at 8:30 a.m. (Eastern Time). You can join the call as follows: Dial in number for live access: 1-877-451-6152 (domestic), 1-201-389-0879 (international)Replay (available 3 hours after the call and available until March 17, 2026): 1-844-512-2921 (domestic), 1-412-317-6671 (international)Passcode for the live call and the replay: 13758

    2/24/26 1:49:54 PM ET
    $SGRY
    Hospital/Nursing Management
    Health Care

    Elevance Health Reports Fourth Quarter and Full Year 2025 Results; Sets Full Year 2026 Outlook

    4Q 2025 operating revenue of $49.3 billion; FY 2025 of $197.6 billion 4Q 2025 diluted EPS1 of $2.47; adjusted diluted EPS2 of $3.33 FY 2025 diluted EPS1 of $25.21; adjusted diluted EPS2 of $30.29 Projected FY 2026 GAAP diluted EPS1 to be at least $22.30 Projected FY 2026 adjusted diluted EPS2 to be at least $25.50 Returned $4.1 billion of capital to shareholders in 2025 Reaffirming long-term earnings algorithm; recalibrating segment margin targets Elevance Health, Inc. (NYSE:ELV) reported fourth quarter and full year 2025 results. "Elevance Health delivered fourth quarter results in line with our outlook, reflecting disciplined execution in a dynamic environment. As

    1/28/26 6:00:00 AM ET
    $ELV
    Medical Specialities
    Health Care